Hemospermia following transrectal ultrasound-guided prostate biopsy: a prospective study

Prostate Cancer Prostatic Dis. 2007;10(3):283-7. doi: 10.1038/sj.pcan.4500955. Epub 2007 Feb 20.


Hemospermia is known to be associated with transrectal ultrasound-guided prostate biopsy (TRUS-PB). The true incidence of hemospermia, its duration and implications are not well established. We performed a prospective observational study involving patients undergoing TRUS-PB for suspected prostate cancer at our institution. Sixty-three eligible men were included in the study. Most men (84%) undergoing TRUS-PB, who were able to ejaculate, experienced hemospermia, which was associated with some degree of anxiety. The mean duration of hemospermia was 3.5 (+/-1.7) weeks. The number of ejaculations before the complete resolution of hemospermia was 8 (+/-6.7). None of the clinical and pathological factors was a significant predictor of the duration of hemospermia. Patients should be adequately counseled before TRUS-PB to avoid undue anxiety and alterations in sexual activity.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biopsy / adverse effects*
  • Hemospermia / etiology*
  • Humans
  • Male
  • Postoperative Complications*
  • Prostatic Neoplasms / surgery*
  • Ultrasonography*
  • Urologic Surgical Procedures, Male / adverse effects*